Literature DB >> 17576183

Prisons, hepatitis C and harm minimisation.

Michael H Levy1, Carla Treloar, Rodney M McDonald, Norman Booker.   

Abstract

Australian prisons have been identified as a focus of the ongoing hepatitis C epidemic. Harm minimisation is the major strategy directed to community-based public health measures to control hepatitis C. Harm-minimisation strategies to protect inmates and workers are incompletely and inconsistently applied in Australian prisons. Overseas experience has demonstrated that introducing injecting-equipment exchange programs and professional tattoo parlours in prisons could at least partially reduce the risks of ongoing hepatitis C transmission, and would support prevention and treatment programs. A two-stage approach is suggested: firstly, implementing programs of proven effectiveness consistently across the eight Australian jurisdictions, and, secondly, expanding current initiatives in the light of international "best practice".

Entities:  

Mesh:

Year:  2007        PMID: 17576183

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  4 in total

1.  Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study.

Authors:  Jenny Iversen; Handan Wand; Libby Topp; John Kaldor; Lisa Maher
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

2.  Acquiring hepatitis C in prison: the social organisation of injecting risk.

Authors:  Carla Treloar; Luke McCredie; Andrew R Lloyd
Journal:  Harm Reduct J       Date:  2015-04-24

3.  Moving beyond non-engagement on regulated needle-syringe exchange programs in Australian prisons.

Authors:  Daniel Mogg; Michael Levy
Journal:  Harm Reduct J       Date:  2009-05-04

4.  Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons.

Authors:  Rochelle E Watkins; Donna B Mak; Crystal Connelly
Journal:  BMC Public Health       Date:  2009-10-13       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.